Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

NCT03278782 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Anaplastic Large Cell Lymphoma
Recurrent Angioimmunoblastic T-Cell Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Anaplastic Large Cell Lymphoma
Refractory Angioimmunoblastic T-Cell Lymphoma
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Romidepsin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]